

# Dennis Dong Hwan Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8445206/publications.pdf>

Version: 2024-02-01

105  
papers

1,585  
citations

411340

20  
h-index

406436

35  
g-index

106  
all docs

106  
docs citations

106  
times ranked

2647  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early prediction of stable MR <sup>&gt;4.5</sup> by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib. <i>Leukemia and Lymphoma</i> , 2022, 63, 162-169.	0.6	1
2	<i>BCR-ABL1</i> transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. <i>British Journal of Haematology</i> , 2022, 196, 136-145.	1.2	4
3	Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. <i>European Journal of Haematology</i> , 2022, 108, 61-72.	1.1	9
4	Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. <i>Haematologica</i> , 2022, 107, 358-370.	1.7	10
5	<i>TET2</i> mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. <i>Blood Advances</i> , 2022, 6, 100-107.	2.5	12
6	Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma. <i>European Journal of Haematology</i> , 2022, 108, 430-436.	1.1	2
7	An improved molecular inversion probe based targeted sequencing approach for low variant allele frequency. <i>NAR Genomics and Bioinformatics</i> , 2022, 4, 1qab125.	1.5	4
8	Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 265.e1-265.e9.	0.6	6
9	Anti-thymocyte Globulin and Post-transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors. <i>European Journal of Haematology</i> , 2022, 108, 288-297.	1.1	4
10	The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. <i>EJHaem</i> , 2022, 3, 873-884.	0.4	2
11	Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	2
12	Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Acta Haematologica</i> , 2021, 144, 66-73.	0.7	11
13	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 60-69.	1.3	26
14	Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. <i>Bone Marrow Transplantation</i> , 2021, 56, 689-691.	1.3	1
15	Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. <i>European Journal of Haematology</i> , 2021, 106, 32-39.	1.1	16
16	Prolactin, a potential biomarker for chronic GVHD activity. <i>European Journal of Haematology</i> , 2021, 106, 158-164.	1.1	2
17	Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing. <i>Bone Marrow Transplantation</i> , 2021, 56, 1159-1170.	1.3	10
18	Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level. <i>Annals of Hematology</i> , 2021, 100, 789-798.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 302-310.	0.6	4
20	Predictors of outcomes of therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	3
21	Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2021, 113, 632-641.	0.7	32
22	Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 1311-1319.	0.8	2
23	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 1908-1918.	1.3	10
24	Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. <i>British Journal of Haematology</i> , 2021, 193, 779-791.	1.2	10
25	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 428.e1-428.e9.	0.6	11
26	Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e559-e568.	0.2	3
27	Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. <i>European Journal of Haematology</i> , 2021, 107, 517-528.	1.1	2
28	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. <i>Leukemia and Lymphoma</i> , 2021, 62, 3373-3383.	0.6	12
29	Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. <i>European Journal of Haematology</i> , 2021, 106, 508-519.	1.1	1
30	Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021, 13, 5543.	1.7	9
31	A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy. <i>Blood</i> , 2021, 138, 3610-3610.	0.6	3
32	Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival. <i>Blood</i> , 2021, 138, 3905-3905.	0.6	0
33	Single-Cell Proteogenomic Sequencing Allows Early Detection of Relapse Clone with CN-LOH at FLT3-ITD Locus from Initial Diagnosis in AML. <i>Blood</i> , 2021, 138, 3428-3428.	0.6	1
34	Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	0
35	My jamais vu in post allogeneic hematopoietic cell transplant: a review on secondary hemophagocytosis in adults. <i>Bone Marrow Transplantation</i> , 2020, 55, 867-872.	1.3	9
36	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2020, 104, 36-45.	1.1	7

#	ARTICLE	IF	CITATIONS
37	High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 3198-3208.	0.6	9
38	RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. <i>Scientific Reports</i> , 2020, 10, 20119.	1.6	6
39	Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 1377-1387.	0.8	15
40	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1511-1519.	2.0	6
41	Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2020, 105, 24-29.	1.1	5
42	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. <i>Bone Marrow Transplantation</i> , 2020, 55, 1773-1783.	1.3	35
43	Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in		

#	ARTICLE	IF	CITATIONS
55	Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. <i>European Journal of Haematology</i> , 2019, 102, 486-493.	1.1	32
56	Are we ready to use precision medicine in chronic myeloid leukemia practice?. <i>Haematologica</i> , 2019, 104, 2327-2329.	1.7	1
57	HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1439-1450.	3.3	14
58	Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1158-1163.	2.0	17
59	Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis. <i>Clinical Hematology International</i> , 2019, 1, 105-113.	0.7	18
60	Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. <i>Blood</i> , 2019, 134, 3344-3344.	0.6	0
61	The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3299-3299.	0.6	0
62	Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. <i>Blood</i> , 2019, 134, 4590-4590.	0.6	0
63	No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient. <i>Blood</i> , 2019, 134, 4514-4514.	0.6	0
64	Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. <i>Annals of Hematology</i> , 2018, 97, 955-965.	0.8	3
65	Efficacy of Cidofovir in Treatment of BK Virus-Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1901-1905.	2.0	35
66	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
67	Therapeutic efficacy of azathioprine in addition to prednisone-based regimens as first-line chronic graft-versus-host disease treatment. <i>Bone Marrow Transplantation</i> , 2018, 53, 334-338.	1.3	2
68	Characteristics, treatment and outcomes of nontuberculous mycobacterial pulmonary disease after allogeneic haematopoietic stem cell transplant. <i>European Respiratory Journal</i> , 2018, 51, 1702330.	3.1	11
69	Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 366-372.	2.0	30
70	Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome. <i>Current Opinion in Hematology</i> , 2018, 25, 425-432.	1.2	20
71	Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era. <i>Leukemia Research</i> , 2018, 73, 67-75.	0.4	2
72	Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies. <i>Annals of Hematology</i> , 2018, 97, 1975-1985.	0.8	7

#	ARTICLE	IF	CITATIONS
73	Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2259-2264.	2.0	66
74	Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. <i>Blood</i> , 2018, 132, 1604-1613.	0.6	84
75	Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. <i>Oncotarget</i> , 2018, 9, 4961-4968.	0.8	19
76	High Incidence but Very Low Mortality of Epstein Barr Virus Related Post-Transplantation Lymphoproliferative Disorder after T-Cell Replete Haploidentical Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 2104-2104.	0.6	0
77	Pregnancy: part of life in chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 280-287.	0.6	20
78	Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. <i>Annals of Hematology</i> , 2017, 96, 805-815.	0.8	12
79	Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1117-1121.	2.0	32
80	Reply to letter to the editor. <i>Leukemia and Lymphoma</i> , 2017, 58, 1273-1274.	0.6	0
81	Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up data. <i>European Journal of Haematology</i> , 2017, 99, 160-168.	1.1	6
82	Long-Term Incidence of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 945-951.	2.0	9
83	Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. <i>Blood</i> , 2017, 129, 38-47.	0.6	95
84	Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 870-878.e1.	0.2	28
85	5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 8305-8314.	0.8	6
86	Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. <i>Annals of Hematology</i> , 2016, 95, 625-635.	0.8	15
87	Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2270-2275.	2.0	17
88	Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia. <i>Journal of Translational Medicine</i> , 2016, 14, 82.	1.8	9
89	Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase. <i>Drugs and Aging</i> , 2016, 33, 335-345.	1.3	0
90	Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. <i>Annals of Hematology</i> , 2016, 95, 301-310.	0.8	26

#	ARTICLE	IF	CITATIONS
91	DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 61-70.	2.0	43
92	Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype. <i>Blood</i> , 2016, 128, 2876-2876.	0.6	0
93	Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. <i>Haematologica</i> , 2015, 100, e351-e353.	1.7	31
94	Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation. <i>American Journal of Hematology</i> , 2015, 90, 392-399.	2.0	17
95	Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e73-e81.	0.2	11
96	Prolonged Duration of Systemic Immunosuppression after Allogeneic Hematopoietic Cell Transplantation Associates with the Use of Peripheral Blood Stem Cells, Severe Grade of Chronic Gvhd, Progressive Type Onset of Chronic Gvhd, Grade 2-4 Acute Gvhd and Older Age, but Not with T-Cell Depletion or Conditioning Regimen. <i>Blood</i> , 2015, 126, 1948-1948.	0.6	0
97	Whole Exome Sequencing Reveals That DNMT3A and ASXL1 Mutation Are Involved in the Development of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia Patients without ABL1 Tyrosine Kinase Domain Mutation. <i>Blood</i> , 2015, 126, 1568-1568.	0.6	1
98	Propensity Score Matching Analysis Demonstrates the Use of Statin Enhances Chance of Achieving MR4.5 in Chronic Myeloid Leukemia Patients in Chronic Phase Following Imatinib Therapy Regardless of Other Clinical Features Including Age of the Patients. <i>Blood</i> , 2015, 126, 4026-4026.	0.6	0
99	A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 87-92.	0.2	21
100	Early lymphocyte recovery at 28 days post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts. <i>European Journal of Haematology</i> , 2014, 93, 273-280.	1.1	21
101	<i>BCR/ABL</i> level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. <i>American Journal of Hematology</i> , 2014, 89, 626-632.	2.0	36
102	Incidence, Risk Factors, and Long-Term Outcomes of Sclerotic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1751-1757.	2.0	15
103	<i>BCR-ABL1</i> transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. <i>British Journal of Haematology</i> , 2013, 160, 630-639.	1.2	26
104	Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset of Chronic Gvhd. <i>Blood</i> , 2012, 120, 4184-4184.	0.6	0
105	Single cell proteogenomic sequencing identifies a relapse-fated AML subclone carrying <i>FLT3-ITD</i> with <i>CN-LOH</i> at chr13q. <i>EJHaem</i> , 0, , .	0.4	1